Investigational drug · Phase 2
ENA-001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Respiratory Depression.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "ENA-001"
First trial start
2026
Dec 15, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ENA-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Respiratory Depression
Approved drugs for the same conditions: Depression (major depressive disorder) · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "ENA-001" as an intervention, largest first.
- ENA-001 for Post Operative Respiratory Depression (PORD)Pivotal-lookingNot yet recruiting
Enalare Therapeutics Inc.Industry
NCT06137638 · 200 participants (planned) · Start Dec 15, 2026 · Primary completion Jun 15, 2027
Drug: ENA-001 · For: Respiratory Depression
Enalare Therapeutics Inc.Industry
NCT06967259 · 62 participants · Start May 14, 2025 · Primary completion Aug 12, 2026
Drug: ENA-001; Placebo Comparator · For: Respiratory Depression
Sites: Miami, Florida; Overland Park, Kansas
Newest research
PubMed records naming it or its code names, newest first.
- Intramuscular ENA-001 Combined With Low-Dose Naloxone Versus Intranasal Naloxone for Reduction of Cardiac Arrest Rate in a Simulated Fentanyl-Xylazine Overdose.
Dahan A, Raffa RB, Pergolizzi JV, et al. · Cureus 2026
- Need for Pharmacologic Targets and Therapeutics for Postoperative Respiratory Depression and Pulmonary Complications in Veterinary Medicine.
Pergolizzi JV, Dahan A, Casazza K, et al. · J Pain Res 2026
- Targeting the Carotid Body Function With Big-K+-Channel Blocker ENA-001 in Opioid-Induced Respiratory Depression: A Scoping Review.
Arevalo JJ, van Velzen M, Jansen SC, et al. · Pharmacol Res Perspect 2026
- Combination of the BK-Channel Antagonist ENA-001 and Naloxone Is More Effective Than Either Agent Alone in Reversing Fentanyl-Induced Respiratory Suppression in Rats.
Phay M, Kwee L, Raffa RB, et al. · Cureus 2026
- ENA-001 Reverses Xylazine/Fentanyl Combination-Induced Respiratory Depression in Rats: A Qualitative Pilot Study.
Miller TL, Mathews J, Dungan GC, et al. · Cureus 2024
- Reversal of Propofol-induced Depression of the Hypoxic Ventilatory Response by BK-channel Blocker ENA-001: A Randomized Controlled Trial.
Jansen SC, van Lemmen M, Olofsen E, et al. · Anesthesiology 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.